Cryo-Cell International Inc. - CCEL STOCK NEWS

Cryo-Cell International, Inc. (NYSE: CCEL), the world's first private cord blood bank, reported its fiscal third quarter 2024 financial results. Highlights include:

- Revenue increased to $8.07 million, up from $7.87 million in Q3 2023
- Net income rose to $1.05 million ($0.13 per share), compared to $681,000 ($0.08 per share) in Q3 2023
- Gains on marketable securities were $522,000, up from $93,000 in Q3 2023

The company is exploring strategic alternatives to maximize shareholder value and considering instituting a regular quarterly dividend. Cryo-Cell's proposed spinoff of Celle Corp. is currently on hold due to a Demand for Arbitration filed with Duke University. The company continues to expand its services, including the launch of ExtraVault for biostorage and distribution solutions.

Cryo-Cell International, Inc. (NYSE American: CCEL), the world's first private cord blood bank, reported its fiscal second quarter 2024 financial results. Key highlights include:

- Revenue increased 3% to $8.0 million, compared to $7.8 million in Q2 2023
- Net income rose to $656,000 ($0.08 per share), up from $221,000 ($0.03 per share) in Q2 2023
- Cost of sales decreased by 6%
- Selling, general and administrative expenses decreased by less than 1%
- R&D expenses were $241,000, down from $305,000 in Q2 2023

The company's improved performance was driven by increased processing and storage fee revenue, which offset declines in public banking revenue.

Cryo-Cell International, Inc. (CCEL) reported fiscal first quarter 2024 financial results with revenues of $7.85 million, a slight increase from the previous year. Net income was approximately $556,000, down from $767,000 in 2023 due to higher expenses.

Cryo-Cell International, Inc. (CCEL) announces the spin-off of its subsidiary, Celle Corp., to maximize shareholder value. Celle Corp. will hold assets not related to cord blood banking, including the Patent and Technology License Agreement with Duke University. The spin-off is expected to occur in the 2nd or 3rd fiscal quarters.

Cryo-Cell International, Inc. (CCEL) announced fiscal year 2023 results with $31.3 million in revenues. The company reported a net loss of $9.5 million due to non-cash charges. Despite this, they plan to transfer assets to a subsidiary for financial flexibility.

Cryo-Cell International, Inc. announces Q3 2023 results with a 2% increase in revenue and a net income of $681,000.

Cryo-Cell International, Inc. (NYSE American LLC: CCEL) reported a 2% increase in revenue for the fiscal second quarter of 2023 compared to the same period last year. Net income for the quarter was $220,976, down from $634,719 in the previous year. The increase in revenue was driven by higher processing and storage fee revenue, while the decrease in net income was primarily due to increased research and development expenses.

Cryo-Cell International, Inc. (CCEL) announced its fiscal first-quarter results for the period ending February 28, 2023. The company reported revenues of $7.82 million, a notable increase from $7.26 million during the same period in 2022. Key revenue components included $7.56 million from processing and storage fees, $32,000 in product revenue, and approximately $231,000 from public banking efforts.

Net income for the quarter was approximately $767,000, or $0.09 per share, slightly down from $832,000 or $0.10 per share a year earlier. The increase in revenue was offset by a 15% rise in selling, general, and administrative expenses. The company remains focused on its transformation into a vertically integrated cellular therapy company.

Cryo-Cell International (CCEL) reported fiscal 2022 results with consolidated revenues of $30.3 million, up from $28.9 million in fiscal 2021. Processing and storage fees led revenue at $29.8 million. Net income grew to $2.8 million or $0.33 per share, compared to $2.1 million or $0.26 per share in 2021. Key factors included a 5% increase in revenue and a 2% decrease in the cost of sales. The company continues to expand services, including a partnership with Duke University and the launch of ExtraVault, enhancing its biostorage capabilities.